BAYN.DE
BAYN.DE
DE000BAY0017
Bayer AG N
Loading chart...

Company Profile

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Related stocks

GSK.L
GSK.L • United Kingdom
GSK PLC ORD 31 1/4P
1,750 GBp
92.79B USD 1Y +7.1%
GSKN.MX
GSKN.MX • United Kingdom
GSK PLC
849 MXN
92.65B USD 1Y +4.4%
SAN.PA
SAN.PA • France
SANOFI
71.52 EUR
96.02B USD 1Y -16.1%
SNY
SNY • France
Sanofi
40.07 USD
96.01B USD 1Y -17.6%
REC.MI
REC.MI • Italy
RECORDATI ORD
53 EUR
12.35B USD 1Y -1.9%
NVO
NVO • Denmark
Novo Nordisk A/S
38.64 USD
170.57B USD 1Y -36%
NOVO-B.CO
NOVO-B.CO • Denmark
Novo Nordisk B A/S
255.25 DKK
168.87B USD 1Y -35%
NOVO-B.CO
NOVO-B.CO • Denmark
Novo Nordisk B A/S
255.25 DKK
168.87B USD 1Y -35%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
34.2% p.a.
Max Drawdown (5Y)
-72.1%
Sharpe Ratio (5Y)
-0.14
Beta Factor
0.84
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Elevated Short-Term Volatility: 3Y volatility (38.3%) is noticeably higher than the 5Y average (34.2%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (34.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -84.5% in the extended horizon.
ende